WINGLORE, YERVOY (Bristol-Myers Squibb Australia Pty Ltd)
Product name
WINGLORE, YERVOY
Date registered
Evaluation commenced
Decision date
Approval time
68 working days (255)
Active ingredients
ipilimumab
Registration type
EOI
Indication
Non-Small Cell Lung Cancer (NSCLC)
WINGLORE, YERVOY (concentrated solution for injection), in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is now also indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.